BMS-986036, a PEGylated fibroblast growth factor 21 analogue for the treatment of non-alcoholic steatohepatitis: A population pharmacokinetics and exposure-response analysis

2018 ◽  
Vol 68 ◽  
pp. S409
Author(s):  
G. Tirucherai ◽  
M. Magnusson ◽  
C. Acharya ◽  
E. Charles ◽  
D. Shevell ◽  
...  
Keyword(s):  
Growth Factor ◽  
Population Pharmacokinetics ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 21 ◽  
Response Analysis ◽  
Fibroblast Growth ◽  
Alcoholic Steatohepatitis ◽  
Exposure Response

Fibroblast growth factor-21 predicts adverse outcome in community-acquired pneumonia

2018 ◽  
Author(s):  
Fahim Ebrahimi ◽  
Carole Wolffenbuttel ◽  
Claudine A Blum ◽  
Beat Muller ◽  
Philipp Schuetz ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Adverse Outcome ◽  
Community Acquired Pneumonia ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth

Effects of anti-inflammatory treatment on fibroblast growth factor-21 in obesity and metabolic syndrome

2019 ◽  
Author(s):  
Fahim Ebrahimi ◽  
Sandrine Urwyler ◽  
Matthias Betz ◽  
Emanuel Christ ◽  
Philipp Schuetz ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Anti Inflammatory

Fibroblast growth factor 21 (FGF21) in hyper- and hypothyroidism, association with metabolic disturbances

2020 ◽  
Author(s):  
Ewa Szczepańska ◽  
Małgorzata Gietka-Czernel ◽  
Piotr Glinicki ◽  
Helena Jastrzębska ◽  
Jadwiga Słowińska-Srzednicka ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Metabolic Disturbances
Sign in / Sign up

Export Citation Format

Share Document